Epstein-Barr virus–associated lymphoproliferative disorders (EBV-LPDs) are shaped by more than viral infection alone. A new review published in Clinical Epigenetics argues that aberrant DNA methylation sits at the center of how these heterogeneous diseases develop, interact with host genetics, metabolic reprogramming, and immune dysregulation, and might ultimately be treated. The review, authored by Dilara Dilmurat, Xiaobo Lei, Ran Wang, and Zhengde Xie, synthesizes current evidence on methylation dysregulation across diverse EBV-LPDs and examines what this means for therapy.
The central biological theme the authors identify is a bidirectional interplay between EBV and the methylation machinery of the cell. According to the review, EBV actively remodels both its own viral epigenome and that of the host cell. This remodeling serves the virus in two ways: it helps maintain latency, the state in which the viral genome persists silently inside infected cells, and it supports immune evasion, allowing infected cells to escape surveillance. In turn, these epigenetic changes promote disease progression in the affected lymphoid tissues.
The review’s background section notes that methylation abnormalities interact with EBV infection, host genetic mutations, metabolic reprogramming, and immune dysregulation, forming a layered molecular landscape that varies across the different disorders grouped under the EBV-LPD umbrella.
On the therapeutic side, the review reports that hypomethylating agents—drugs that reduce DNA methylation—have demonstrated clinical activity in selected lymphoma cohorts. Notably, the authors state that these agents can directly remodel the EBV epigenome in vivo, meaning that treatment does not only affect the host cell genome but can also alter methylation patterns on the viral genome itself. This dual effect makes hypomethylating therapy of particular interest in EBV-driven disease, where viral epigenetic state and tumor behavior are intertwined.
However, the review is careful about the strength of the clinical evidence. Most combination trials of epigenetic therapies, the authors note, have not prospectively stratified patients by EBV status. Without knowing whether participants’ tumors are EBV-positive or EBV-negative, it is difficult to determine whether the virus itself modifies treatment response. This gap in trial design is flagged as a major limitation of the existing literature.
A second therapeutic concept receiving attention is “epigenetic priming.” In this strategy, transient epigenetic reprogramming is applied before sequential chemotherapy, immunotherapy, or cellular therapy, with the aim of making malignant cells more vulnerable to the treatments that follow. The review states that this approach is supported by growing preclinical and clinical evidence, but it also cautions that the EBV-specific therapeutic benefit of priming remains to be established. In other words, priming may work, but whether it works differently, or better, in EBV-associated disease is still an open question.
The authors’ conclusion balances promise against translational barriers. Aberrant DNA methylation, they write, contributes to the pathobiology of several EBV-LPDs and represents a potentially actionable therapeutic vulnerability in selected subtypes. Yet two obstacles stand in the way of routine clinical application: the absence of standardized epigenetic biomarkers to guide patient selection, and the lack of prospective stratification by EBV status in clinical studies. Until these are addressed, methylation-targeted approaches cannot be reliably matched to the patients most likely to benefit.
Looking forward, the review sets out priorities for future research. These include biomarker-guided epigenetic strategies, prospective assessment of EBV status in clinical trials, and preclinical validation of emerging approaches such as CRISPR/dCas9 epigenome editing. As an open-access review published on 23 September 2026, the article is presented as an early shared version that remains subject to further edits before the final Version of Record. Its overall message is measured: methylation dysregulation is a credible and potentially druggable axis in EBV-LPDs, but converting that biology into validated, EBV-stratified treatments will require the biomarker work and trial designs the authors describe.
Subject of Research: DNA methylation dysregulation in Epstein-Barr virus–associated lymphoproliferative disorders and its therapeutic implications
Article Title: DNA methylation dysregulation in EBV-associated lymphoproliferative disorders: molecular mechanisms and therapeutic advances
Article References: Dilmurat, D., Lei, X., Wang, R., & Xie, Z. (2026). DNA methylation dysregulation in EBV-associated lymphoproliferative disorders: molecular mechanisms and therapeutic advances. Clinical Epigenetics. https://doi.org/10.1186/s13148-026-02241-7
Image Credits: AI Generated
DOI: 10.1186/s13148-026-02241-7
Keywords: Epstein-Barr virus, DNA methylation, lymphoproliferative disorders, epigenetics, hypomethylating agents, epigenetic priming, CRISPR dCas9, immune evasion, viral latency, biomarkers, Clinical Epigenetics, methylation
News Source: Juliet Wilcox. (October 29, 2026). EBV-driven lymphoproliferative disorders show disrupted DNA methylation patterns. Scienmag.
